sonrotoclax   Click here for help

GtoPdb Ligand ID: 13354

Synonyms: BGB-11417 | BGB11417 | compound 12e [PMID: 38695063]
Compound class: Synthetic organic
Comment: Sonrotoclax (BGB-11417) is a B-cell lymphoma-2 (Bcl-2) selective antagonist that was designed for the treatment of Bcl-2-driven B-cell malignancies, in particular for cancers that are resistant to venetoclax [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 4
Rotatable bonds 14
Topological polar surface area 187.12
Molecular weight 890.1
XLogP 7.46
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C1=C(C=CC=C1)[C@@H]2CCCN2C3CC4(CCN(CC4)C5=CC=C(C(=C5)OC6=CC7=C(NC=C7)N=C6)C(=O)NS(=O)(=O)C8=CC=C(C(=C8)[N+](=O)[O-])NCC9CCC(C)(CC9)O)C3
Isomeric SMILES CC(C)C1=CC=CC=C1[C@@H]2CCCN2C3CC4(C3)CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NCC7CCC(CC7)(C)O)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9
InChI InChI=1S/C49H59N7O7S/c1-32(2)39-7-4-5-8-40(39)43-9-6-22-55(43)36-28-49(29-36)19-23-54(24-20-49)35-10-12-41(45(26-35)63-37-25-34-16-21-50-46(34)52-31-37)47(57)53-64(61,62)38-11-13-42(44(27-38)56(59)60)51-30-33-14-17-48(3,58)18-15-33/h4-5,7-8,10-13,16,21,25-27,31-33,36,43,51,58H,6,9,14-15,17-20,22-24,28-30H2,1-3H3,(H,50,52)(H,53,57)/t33?,43-,48?/m0/s1
InChI Key ZQTKOYMWCCSKON-HCWAPQBJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
Sonrotoclax (BGB-11417) inhibits the function of wild type Bcl-2 and Bcl-2G101V in vitro and in vivo [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
BCL2 apoptosis regulator Hs Antagonist Antagonist 9.5 – 10.7 pIC50 - 1
pIC50 10.7 (IC50 1.9x10-11 M) [1]
Description: Potency vs. wild type hBCL2 determined in a biochemical assay
pIC50 9.5 (IC50 3.4x10-10 M) [1]
Description: Potency vs. hBCL2G101V determined in a biochemical assay